Compare PCT & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCT | XERS |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2020 | 2021 |
| Metric | PCT | XERS |
|---|---|---|
| Price | $7.15 | $8.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $13.00 | $10.83 |
| AVG Volume (30 Days) | ★ 4.3M | 1.6M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 30.86 | ★ 100.00 |
| EPS | N/A | ★ N/A |
| Revenue | $8,355,000.00 | ★ $49,590,000.00 |
| Revenue This Year | $380.44 | $34.37 |
| Revenue Next Year | $203.33 | $22.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $4.93 | $5.25 |
| 52 Week High | $15.49 | $10.08 |
| Indicator | PCT | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 50.03 | 55.68 |
| Support Level | $5.02 | $6.98 |
| Resistance Level | $9.56 | $8.42 |
| Average True Range (ATR) | 0.48 | 0.32 |
| MACD | 0.18 | -0.02 |
| Stochastic Oscillator | 61.19 | 82.73 |
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.